Medical progress today | spotlight: we smell a rat
Medical Progress Today | Spotlight: We Smell A Rat
We Smell A Rat
Tests in rats shouldn't kill a promising new drug for RLS. David R. Henderson, Charles L. Hooper
Which group should the U.S. Food and Drug Administration care about more:
humans or rats? That's not a trick question. The FDA's recent decision to
reject the drug Horizant suggests that, at least in this case, it cares more
about rats. And because of the FDA's decision, some people (not rats) with
restless legs syndrome (RLS) will suffer more.
Here are the facts. is a next-generation version of gabapentin. It is
just like the original gabapentin except that it is more easily transported
through the intestinal wall. That is the crucial fact to know in order to
understand how strange and destructive was the FDA's rejection of Horizant.
In 1993, Pfizer launched gabapentin, with the brand name , for
treating seizures, postherpetic neuralgia, neuropathy, and other nerve pain.
The FDA approved Neurontin even though, in animal testing, some male rats
given ten times the highest human dose got a certain type of pancreatic
cancer. Yet the rats still did fine. The tumors did not metastasize, were not
locally invasive, and did not affect the rats' survival. Interestingly, neither
mice nor female rats given gabapentin developed the tumors. And, most
important, neither did humans. We have had seventeen years of experience
with Neurontin with no reported increase in pancreatic cancer. The FDA even
acknowledges this fact. That should be enough, right?
Not for the FDA. Not surprisingly, GlaxoSmithKline's and XenoPort's drug
Horizant showed these same tumors in male rats given up to twenty-five
times the highest human dose. "[P]reclinical finding of
pancreatic acinar cell tumors in rats was of sufficient concern to preclude
approval of Horizant for RLS at this time."
It gets worse. XenoPort's CEO, Ron Barrett, stated that the FDA had never
raised the issue in its many discussions with XenoPort. Moreover, Mr. Barrett,
who has actually seen the FDA's rejection letter, claimed, in a conference call
to explain the FDA's decision, that the FDA had determined that Horizant was
Moreover, researchers have previously shown that the rat pancreatic exocrine
tumors induced by gabapentin do not correspond to human tumors. Acinar
cell carcinoma was very uncommon in humans before Neurontin launched,
Remember that the whole purpose of testing new drugs in humans is to look
for possible dangers. That is exactly why Horizant was tested in clinical trials.
Is the FDA now going to admit that clinical trials aren't that useful? And if
they aren't, why does it persist in requiring them?
Now, you might say that with Neurontin already on the market, rejecting
Horizant is no big deal. But it is a big deal. Neurontin is short-acting and
requires a high dose to produce a certain blood level, while Horizant requires
less to achieve the same effect since it is more efficiently transported through
the intestinal wall. In other words, Horizant is more convenient and effective
because it can be dosed lower and/or less frequently than Neurontin's three-
times-per-day regimen and still provide more stable levels in the blood. Ask
Medical Progress Today | Spotlight: We Smell A Rat
almost any doctor what his biggest frustration is with patients and medicines,
and he will likely tell you that it's hard to get patients to keep taking their
pills. Easier dosing causes patients to better adhere to their therapy.
There are only two approved medications for restless legs syndrome.
Unfortunately, they are associated with significant side effects and actually
characterized by unpleasant sensations in the legs and an uncontrollable urge
to move them for relief. People with RLS report feelings of burning, creeping,
or tugging, and they sometimes feel as if they have insects crawling inside
their legs. The sensations range in severity from uncomfortable to painful.
RLS is generally a life-long condition for which there is no cure. These
sufferers can now thank the FDA for making them suffer for a lifetime.
Beyond the damage inflicted on people with RLS is the damage inflicted on
drug companies. Drug companies are in the business to make money by
curing or ameliorating disease. When the FDA gives them the green light to
go beyond animal studies and do the more-expensive studies on humans,
drug companies believe that they have some assurance that if the drug
works on humans without untoward side effects, the FDA will approve the
drug. But now the FDA has established a bad precedent. It can say, in effect,
"We know we approved this next phase of testing, but we’ve changed our
minds. We're worried about the effect on rats that we ignored earlier." This
creates enormous uncertainty for drug companies. If they see this decision
on Horizant as a precedent, they will be less likely to invest in new
medicines. And that will hurt all of us.
Seventeen years of human data in millions of patients showing that
gabapentin doesn't cause pancreatic cancer in humans were trumped by a
two-year study in 200 rats given extremely high doses. The real danger to
our health comes from such myopic views of safety and a hyperconservative,
opaque, and capricious FDA keeping useful medicines out of the hands of
American doctors and patients. The FDA needs to be reminded that it is
reviewing drugs for humans, not for rodents. David R. Henderson, a research fellow with the Hoover Institution and an economics professor at the Naval Postgraduate School, was formerly thesenior economist for health policy with President Reagan's Council ofEconomic Advisers. Charles L. Hooper is president of Objective Insights, a company that consults for pharmaceutical and biotech companies, and avisiting fellow with the Hoover Institution.
FOR IMMEDIATE RELEASE T2 Biosystems Demonstrates First-Ever Ability to Accurately and Rapidly Detect Systemic Candida Infection Directly in Whole Blood in Single-Process Test Data Presented at Annual Meeting of Mycoses Study Group Demonstrates Rapid Identification of the Most Deadly Form of Common Hospital-‐Acquir
Fax this order form to 0800 11 333 Or e-mail it to [email protected] 1. Administrative data To be filled in by salesperson Type of contract Follow-up BCI opportunity no.: …………………………………………………………………………………………………………… Seller type External resel ing partner (indirect sales) Seller data